In a Dutch cohort (n = 408) of early-RA patients, Amkreutz et al. showed a lower BMD in the spine and hip of ACPA-positive patients than in ACPA-negative patients at the baseline, without the influence of ACPA levels and without significant changes over time. This evidence concerns the gene PRTN3 and rheumatoid arthritis.